Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buquinolate is a synthetic small molecule belonging to the hydroquinolone class, structurally characterized as a quinoline derivative. It was developed and used as an anticoccidial agent in poultry, specifically for the prevention of coccidiosis in broilers and layers. The drug was approved by the U.S. FDA for this veterinary use but has since been withdrawn from the market[3][4]. Its mechanism of action is presumed to involve inhibition of mitochondrial respiration in Eimeria species (the causative agents of coccidiosis), likely targeting components of the protozoan respiratory chain, similar to other quinolone-based anticoccidials[6]. Medicated birds treated with buquinolate showed improved egg production and weight gain during its period of use[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buquinolate.